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Abstract
Purpose—The ubiquitin-proteasome pathway has been validated as a target in non-Hodgkin
lymphoma through demonstration of the activity of the proteasome inhibitor bortezomib.
Experimental Design—Another potentially attractive target is the human homologue of the
murine double minute-2 protein, HDM-2, which serves as the major p53 E3 ubiquitin ligase, and we
therefore evaluated the activity of a novel agent, MI-63, which disrupts the HDM-2/p53 interaction.
Results—Treatment of wild-type p53 mantle cell lymphoma cell lines (MCL) with MI-63 resulted
in a dose- and time-dependent inhibition of proliferation, with an IC50 in the 0.5-5.0 μM range. MI-63
induced p53 and HDM-2 accumulation, as well as other downstream p53 targets such as p53-
upregulated modulator of apoptosis and p21Cip1. This was associated with cell cycle arrest at G1/S,
activation of caspases-3, -8 and -9, cleavage of poly-(ADP-ribose) polymerase, and loss of E2F1.
HDM-2 inhibition caused phosphorylation of p53 at multiple serine residues, including 15, 37 and
392, which coincided with low levels of DNA strand breaks. DNA damage occurred in a small
percentage of cells, and did not induce phosphorylation of the DNA damage marker H2A.XSer139.
Combinations of MI-63 with the molecularly targeted agents bortezomib and rapamycin showed
synergistic, sequence-dependent anti-proliferative effects. Treatment of primary MCL patient
samples resulted in apoptosis and induction of p53 and p21, which was not seen in normal controls.
Conclusions—These findings support the hypothesis that inhibition of the HDM-2/p53 interaction
may be a promising approach both by itself, and in combination with currently used
chemotherapeutics, against lymphoid malignancies.
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Non-Hodgkin lymphomas (NHL) are a complex group of lymphoid malignancies showing a
wide range of pathobiology and clinical behavior (1). Mantle cell lymphoma (MCL) is a distinct
NHL subgroup accounting for 6-8% of all lymphoid malignancies, which displays the
immunophenotype of a B-cell lymphoma (2,3). At the molecular level, MCL is characterized
by the presence of an 11;14 translocation resulting in the overexpression of Cyclin D1.
Clinically, MCL presents in elderly patients and follows an aggressive course, with relapse
occurring almost invariably despite good initial outcomes to conventional chemotherapies
(2). One recent encouraging development has been the approval of the proteasome inhibitor
bortezomib (VELCADE®) after demonstration of its clinical activity in the relapsed/refractory
setting (4-6). This agent has helped to validate the ubiquitin-proteasome pathway as a target
for NHL therapy, and pre-clinically resulted in part in accumulation of p53, and down-stream
targets such as p21Cip1 (7).
Another mechanism by which p53 turnover can be impacted is by targeting p53 ubiquitination,
a necessary precursor prior to its proteasome-mediated degradation. The murine double minute
(MDM)-2 protein, and its human homologue, HDM-2, are the major E3 ligases responsible
for p53 ubiquitination (8). HDM-2 is an oncogene that is over-expressed in a variety of
malignancies, including leukemias, sarcomas, and solid tumors (9), and may play a role in
NHL as well (10). In addition to its E3 ligase activity, HDM-2 also inhibits p53 function through
binding to the NH2-terminus of p53 and suppressing its transcriptional activation properties
(8). Under conditions of cellular stress, the ability of HDM-2 to bind p53 is blocked, preventing
HDM-2 from inhibiting p53 function. This results in a rise in p53 levels, cell cycle arrest,
induction of apoptosis, and senescence (11,12).
Small molecule inhibitors of the interaction between HDM-2 and p53 such as nutlin restore
p53 function in tumor cells with wtp53 (13,14). Nutlin binds in the p53-binding pocket of
HDM-2 and displaces p53, resulting in stabilization of p53, p21 expression, cell cycle arrest,
apoptosis and growth inhibition (13). These effects were found to be specific for malignancies
with wtp53, did not induce p53 phosphorylation, and had a limited effect on primary cells.
Recent work has found that, although nutlin acts through the HDM-2/p53 interaction, other
cellular targets have been identified, including the cell cycle regulator E2F1 (15), the androgen
receptor (16), hypoxia-inducible factor (17), and the nuclear factor-κB pathway (18). The
potential to target the HDM-2/p53 interaction has not been evaluated in models of NHL,
however, and given the above rationale, its potential utility in MCL was of interest.
Materials and Methods
Reagents
The HDM-2 inhibitor MI-63 was provided by Ascenta Therapeutics, Inc. Nutlin-3 (NUT),
mechlorethamine (MCT), doxorubicin (DOX), pifithrin-α (PIFT), and rapamycin (RAP) were
purchased from Sigma-Aldrich, while bortezomib (BZB) and cisplatin (CISP) were from the
University of North Carolina clinical pharmacy.
Cell culture and patient samples
JVM-2, GRANTA-519, REC-1, Jeko-1, Karpas-422, BL-41, and WSU-NHL cells were
purchased from the German Collection of Microorganisms and Cell Cultures, while CCRF-
CEM were purchased from the American Type Culture Collection. Cells were grown in RPMI
1640 (Invitrogen) supplemented with 10% fetal bovine serum (Sigma-Aldrich), 100 U/ml
penicillin, and 100 μg/ml streptomycin, except GRANTA-519, which were grown in DME-M
(Invitrogen). Patient samples were collected and purified as previously described (19).
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Total RNA was isolated using an RNeasy Plus kit (Qiagen) and cDNA was synthesized using
Superscript II (Invitrogen). PCR was performed for 30 cycles, unless indicated otherwise, for
p53-upregulated modulator of apoptosis (PUMA; GenBank™ accession number:
NM_014417) using sense primer 5′-CGGCGGAGACAAGAGGAGCA-3′ and antisense
primer 5′-GTGAAGGAGCACCGAGAGGAGA-3′. Primers and conditions for p21Cip1 and
β2-microglobulin (β2M) were as previously described (20,21).
Immunoblot
Protein expression in drug-treated cells was measured by immunoblot analysis performed as
previously described (21). Antibodies to p53, HDM-2, E2F1, and ubiquitin were purchased
from Santa Cruz Biotechnologies, while anti-phospho-p53 and anti-poly-(ADP-ribose)
polymerase (PARP) antibodies were from Cell Signaling Technologies and anti-β-Actin was
from Sigma-Aldrich.
Cell cycle analysis
Cells were treated with drug for 24 hours, then fixed and stained with propidium iodide (Sigma-
Aldrich). Cell cycle data were analyzed on a FacsCalibur (Becton-Dickson) using FlowJo v.
6.3.3 (Tree Star, Inc.).
Flow cytometry
Levels of total p53, phospho-Ser15-p53, H2A.X-Ser139 and cleaved caspase-3 were measured
by flow cytometry after cells were fixed in paraformaldehyde and then permeabilized in 100%
methanol. Antibodies to cleaved caspase-3 and H2A.X-Ser139 were purchased from Cell
Signaling Technologies.
ELISA for p21 and phospho-p53-Ser15
Cells were treated with vehicle control, 5μM MI-63, nutlin, or 0.5μM DOX. ELISAs were
performed using a p21 (Assay Designs) or a phospho-p53-Ser15 ELISA kit (Cell Signaling
Technology) according to the manufacturer’s instructions. p21 levels were expressed in μg/ml
calculated from the recommended standard curve, while the fold induction in phospho-p53-
Ser-15 content was determined from the absorbance values and normalized to untreated
controls from triplicate experiments.
Caspase activation assay
Activation of caspases was evaluated in cell lysates as previously described (19). The pan-
caspase inhibitor Z-VAD and caspase-8 and -9 inhibitors were purchased from Calbiochem
and used at concentrations of 50μM.
DNA damage assays
Cells were treated as indicated in the text, and DNA damage was measured using the Trevigen
Comet Assay Kit. Apurinic and apyrimidinic DNA damage was measured using the DNA
Damage Quantification Kit (Biovision).
Cell proliferation assay
The WST-1 reagent (Roche Diagnostics) was used to determine the effects of HDM-2
inhibitors on cell proliferation and their relative IC50 as previously published (19).
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To evaluate for the presence of synergistic interactions, the methods of Chou and Talalay were
used (22,23). Briefly, MI-63, DOX, CISP, BZB, or RAP were added to cells, and the IC50 of
each drug individually was determined using the WST-1 assay. The calculated IC50 was then
designated 1xIC50, and similar determinations were made at 0.25x, 1x, 2x, and 4x the IC50.
MI-63 and the other chemotherapy drugs were used in a 1:1 ratio and added simultaneously to
the cells for 3 days and WST-1 assays were performed. Data were then analyzed using
CalcuSyn software (Biosoft), and combination indices (CI) were calculated.
Results
MI-63 inhibits the growth of NHL cell lines
The HDM-2 inhibitor MI-63 has been shown to bind HDM-2 in vitro with a Ki of 3 nM, and
was effective in the activation of p53 resulting in inhibition of growth of epithelial cancer cell
lines (24,25). To evaluate its impact on NHL, cell lines of varying p53 status (Supplementary
Table 1) were treated with MI-63 for 3 days, and IC50 values were calculated using a cell
viability assay. MCL cell lines with wild-type p53 (wtp53; JVM-2, Granta-519 and REC-1)
were sensitive to MI-63, with IC50 values ranging from 0.79-1.12 μM (Fig.1A, left). However,
an MCL cell line with mutant p53 (mutp53; Jeko-1) was relatively resistant, with an IC50 of
almost 12 μM. A second panel of cells representing different NHL histologies was also studied
(Fig.1A, right), and three of the mutp53 cell lines (CCRF-CEM, BL-41 and KARPAS-422)
were again relatively resistant to MI-63. Interestingly, the mutp53 Waldenström’s cell line
WSU-NHL was sensitive, with an IC50 of 1.95μM.
HDM-2 inhibition should stabilize p53 and induce up-regulation of HDM-2, since it is itself a
p53 target. MCL wtp53 cell lines treated with MI-63 for 24 hours indeed revealed an increase
in total p53 levels (Fig.1B and supplementary Fig.1) similar to that seen with doxorubicin,
while no change was seen in mutp53 Jeko-1 cells. HDM-2 levels increased significantly in
MI-63-treated JVM-2 and Granta-519 cells, though only a slight increase was noted in REC-1
cells, and no change was seen in Jeko-1 cells. To determine if these findings correlated with
triggering of apoptosis, the late stage apoptosis marker PARP was studied, and found to be
cleaved in wtp53 MCL lines at concentrates equal to or greater than 5μM.
We also examined the effect of MI-63 on p53 in the mutp53 lines, and in the two where p53
was detectable, WSU-NHL and CCRF-CEM, total p53 levels did not change significantly (Fig.
1B and supplementary Fig.1). No HDM-2 expression was seen in either Jeko-1 or WSU-NHL
cells, but in CCRF-CEM cells, MI-63 induced a paradoxical decrease in HDM-2 levels. A
noticeable effect was seen on PARP in the CCRF-CEM and WSU-NHL cell lines, where MI-63
at 5μM and greater induced cleavage that was equivalent to, or greater than that seen with
doxorubicin. This lack of change in p53 levels with continued induction of PARP cleavage
may point to the presence of p53-independent mechanisms of action for HDM-2 inhibitors in
these cell backgrounds.
Given the possible relevance of p53-independent mechanisms, it was of interest to determine
if any of the mechanism of action of MI-63 was dependent on functional wtp53. Pifithrin-α
inhibits p53-dependent transcription and p53-mediated apoptosis (26), and should therefore
reverse some of the effects of MI-63 treatment of wtp53 cells. Indeed, Granta-519 cells exposed
to PIFT in combination with MI-63 were partially rescued from cell death (Fig.1C), and a
similar effect was seen with nutlin. Thus, p53-dependent mechanisms are important to the
mechanism of action of these HDM-2 inhibitors. The incomplete rescue may indicate another
secondary, p53-independent mechanism may also be active, or incomplete suppression of p53
by PIFT in these experiments.
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MI-63 induces upregulation of p53 target genes
We next examined the ability of MI-63 to upregulate the downstream p53 target genes p21 and
PUMA by evaluating their transcript levels with RT-PCR. Both p21 and PUMA increased in
response to MI-63 in the wtp53 MCL cell lines (Fig.2A and supplementary Fig.2A). The
mutp53 WSU-NHL had a small increase in p21 and PUMA by RT-PCR (Fig.2A and
supplementary Fig.2A ), but no change was seen in Jeko-1 or CCRF-CEM. p21 protein levels
were measured with a quantitative ELISA to determine if this increased transcript level resulted
in increased protein abundance. Protein lysates from MCL, WSU-NHL and CCRF-CEM that
had been treated with MI-63 demonstrated that wtp53 MCL cells had an increase in p21 protein,
which was especially marked in JVM-2 cells (Fig.2B). In contrast, mutp53 Jeko-1, WSU-NHL
and CCRF-CEM cells demonstrated little to no baseline p21 expression, and no increase with
MI-63.
The HDM-2 inhibitor nutlin has previously been shown to induce cell cycle arrest (13,16,27,
28), so we examined NHL cells treated with MI-63 for a similar effect. wtp53 MCL cells
showed a G1/S cell cycle arrest after 5μM MI-63, with REC-1 cells being the most affected
(Fig.2C). Jeko-1 and WSU-NHL mutp53 cells had no evidence of cell cycle arrest, but they
did arrest in G2/M after treatment with DOX (Supplementary Fig.2B). These results suggested
that MI-63 acted similarly to nutlin in its ability to induce p21 and a G1/S cell cycle arrest.
MI-63 induces caspase-mediated cell death
To further define the mechanism of cell death in MI-63-exposed cells, we measured caspase-3,
-8, and -9 activities in MI-63-treated MCL cells. All wtp53 MCL cells had an increase in
caspase-3 activity, ranging from a 3-fold increase in REC-1, to an 8-fold increase in JVM-2
(Fig.3A). This was associated with an increase in caspase-8 activity to some extent in all of
these cells, particularly REC-1, and may indicate a death receptor-mediated mechanism of cell
death. Caspase-9 activation was more variable, and seen predominantly in REC-1, while
mutp53 Jeko-1 cells, in contrast, showed little if any activation of these caspases. The
incubation of the pan-caspase inhibitor Z-VAD with MI-63 resulted in a partial rescue of cell
death in REC-1 (Supplementary Fig.3A), and a similar effect was seen with nutlin. Inhibition
of caspases-8 and -9 individually in cells treated with either MI-63 or nutlin showed little to
no ability to rescue cell viability.
The time course of caspase-3 induction was also measured in JVM-2 and REC-1 cells.
Caspase-3 activity began to rise 3 hours after addition of MI-63, peaked after 12 hours, and
then began to fall, whereas activity in DOX-treated cells continued to increase up to 24 hours
in JVM-2 (Fig.3B). REC-1 cells showed a slower onset of caspase-3 activation in that levels
did not rise until 6 hours after addition of MI-63 or DOX, then peaked at 12 hours, and began
to fall at 24 hours for both agents (Supplementary Fig.3B). Accumulation of p53 was also rapid
following MI-63 treatment in both cell lines, with increased p53 levels seen as early as 3 hours,
which continued to be elevated above baseline even after 24 hours (Fig.3C and supplementary
Fig.3C). We also noticed that the abundance of the cell cycle regulator E2F1 decreased after
addition of MI-63 after 3 hours, and was lost almost completely by 12 and 24 hours in JVM-2
and REC-1 cells, respectively.
HDM-2 inhibitors induce p53 phosphorylation
Interference with the HDM-2/p53 interaction by nutlins has previously been shown to induce
cell death in the absence of genotoxic effects as measured by the phosphorylation status of p53
at Serine-15 (13). It was therefore of interest to determine if this was also the case in our MCL
models, since it could indicate that adding genotoxic drugs such as alkylating agents to HDM-2
inhibitors may enhance anti-NHL activity. Notably, treatment with both MI-63 and nutlin
resulted in the appearance of p53 phosphorylated at serines-15, -37, and -392 (Fig.4A), though
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to a lesser extent than with the known genotoxic agent DOX. Since ataxia telangiectasia-
mutated (ATM) protein kinase is responsible for phosphorylation of p53 at serines-15 and -37
in response to DNA damage, we determined its expression levels. No change in the abundance
of total ATM was detected after treatment with MI-63 or nutlin, nor was there any alteration
of expression of activated ATM, which is phosphorylated at Ser-1981.
To further investigate the phosphorylation of p53, we quantitatively measured phospho-p53-
Ser-15 levels by an ELISA. The wtp53 cells JVM-2, GRANTA-519, and REC-1 each had
increases in phospho-p53 abundance (Supplementary Fig.4A), ranging from a two to three-
fold increase in REC-1 and Granta-519, to a 14-fold increase in JVM-2. In addition, the time
course of p53 phosphorylation was studied, and phospho-p53-Ser-15 levels rose as early as 3
hours after exposure to MI-63 (Supplementary Fig.4B), as was the case for total p53 levels.
Levels peaked at 6-12 hours after exposure, at which time the first evidence of PARP cleavage
was seen.
As p53 phosphorylation is associated with damage to DNA (reviewed in (29)), we used the
comet assay to determine whether HDM-2 inhibition was inducing DNA damage. JVM-2 cells
treated with DOX suffered extensive DNA damage as indicated by the development of large
comet tails (Fig.4B). While MI-63 and nutlin did not induce comet tails to the same extent,
MI-63 did nonetheless produce a halo effect around cells, suggesting the presence of early
DNA damage that was not seen after vehicle treatment. To further evaluate for the presence
of DNA damage, we next studied cells for the presence of apurinic and apyrimidinic (AP) DNA
lesions formed during base excision and repair of oxidized, deaminated, or alkylated bases.
JVM-2 cells treated with MI-63 were found to contain 2.0×105 AP lesions per base pair
(Supplementary Fig.4C), compared to 3.7×105 AP lesions for cells treated with the alklyating
agent mechlorethamine. Interestingly, no increase in AP lesions was seen in nutlin-treated cells,
and may indicate an off-target effect for MI-63.
To further characterize the p53-phosphorylation and apparent DNA damage in situ, we
combined phospho-Ser15-p53 or total p53 immunostaining with either cleaved caspase-3, or
the surrogate DNA double strand break marker phospho-H2AX (30,31). In JVM-2, neither
MI-63 nor nutlin induced a significant increase in H2AX expression compared to vehicle-
treated cells, despite inducing strong caspase-3 cleavage (Fig.4C, top panel). Moreover, this
H2AX expression was not linked to expression of phospho-Ser-15-p53 (Fig.4C, middle panel),
with only 7% of cells expressing both p53-phospho-Ser-15 and H2AX after treatment with
MI-63 or nutlin. In contrast, cisplatin treatment resulted in 46% of cells expressing both p53-
phospho-Ser-15 and H2AX. These results were further confirmed by evaluating total p53 and
H2AX (Fig.4C, lower panel), which showed that total p53 levels increased in response to MI-63
or nutlin, while little to no increase was seen in the number of cells expressing H2AX compared
to cisplatin. These findings indicate that low levels of DNA damage occurred in a small
percentage of cells after HDM-2 inhibition, but the damage was not significant enough to elicit
DNA response pathways as measured by ATM and H2AX phosphorylation.
MI-63 synergizes with other molecularly targeted therapeutics
Given the finding that HDM-2 inhibition resulted in little to no DNA damage, it was of interest
to determine if the activity of these agents in vitro could be augmented by DNA damaging
drugs. We combined MI-63 with either cisplatin or doxorubicin using JVM-2 as a model
system. Under some conditions, there did appear to be an additive impact on JVM-2 viability
(Fig.5). Interestingly, interaction analysis failed to show combination indices documenting
synergy (Table 1). Two other agents that have recently shown promise against MCL are the
targeted drugs bortezomib (BZB) and rapamycin (RAP)(32). Enhanced anti-proliferative
activity was seen with the MI-63 and rapamycin combination, and also with MI-63 and
bortezomib (Fig.5). Interaction analysis showed that both RAP and BZB were synergistic with
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MI-63 over all IC50 doses, and this synergy was especially marked with RAP, while the BZB
synergy was weaker (Table 1).
The effectiveness of combination chemotherapy may in some cases depend upon the order of
drug administration (33). We therefore examined whether MI-63 would be more or less
effective at inhibiting cell proliferation depending upon the exposure sequence to other
chemotherapeutics. Pretreatment of JVM-2 with the IC50 of MI-63, followed 24 hours later by
addition of the IC50 of DOX, CISP, BZB, or RAP, was not more effective at inhibiting
proliferation than MI-63 alone (Supplementary Fig.5). However, pretreatment with the IC50
of the chemotherapeutic for 24 hours followed by the IC50 of MI-63 for 24 hours was far more
efficient at inhibiting cell growth. The proteasome inhibitor BZB was particularly effective at
inhibiting cell growth in this assay. Pretreatment of cells with MI-63 followed by chemotherapy
resulted in lower levels of p53 accumulation due to the low IC50 doses used compared to MI-63
alone (Supplementary Fig.5), whereas when the chemotherapeutic was given first and then
followed by MI-63, the ability of MI-63 to induce p53 was restored. Notably, neither DOX nor
CISP in combination with MI-63 was more effective at inducing p53 expression compared to
MI-63 alone when the chemotherapeutic agent was given second. However, when MI-63 was
given after the chemotherapeutic agent, p53 accumulation was markedly enhanced. Similar
findings were seen with BZB and RAP, which induced greater expression of p53 only when
cells were exposed first to these agents and then later to MI-63 (Supplementary Fig.5).
MI-63 effects in patient-derived samples
As inhibition of HDM-2 function in MCL cell culture models showed promising efficacy, we
evaluated the ability of MI-63 and nutlin to affect normal peripheral blood mononuclear cells
(PBMCs) and lymphoma cells. Peripheral blood from normal healthy donors and a newly
diagnosed patient with blastoid MCL (MCL-1) were purified, and treated with a range of doses
of MI-63 or nutlin. Both agents inhibited the growth of MCL cells, with IC50 values of 6.4 and
7.6μM, respectively (Fig.6A). In contrast, neither agent reached its IC50 against the normal
PBMC samples, even at doses up to 100μM, suggesting a degree of selectivity for malignant
cells. Finally, incubation of MCL-1 with MI-63 or nutlin resulted in the accumulation of p53
and an increase in p21 expression (Fig.6B), even in the absence of a clear increase in HDM-2.
Notably, both nutlin and MI-63 were more effective at inducing p53 and p21 than doxorubicin.
Discussion
MCL is an aggressive B-cell lymphoproliferative disorder in which standard chemotherapeutic
regimens have limited efficacy, in that though they can induce remissions these responses are
typically short-lived (34,35). The inability to cure MCL has accelerated research into the field
of molecularly targeted drugs that may have enhanced efficacy with manageable side effect
profiles. Oncotherapeutics often harness the ability of cells to induce apoptosis in response to
DNA damage, but genotoxic agents frequently result in non-specific side effects with selection
of drug-resistant clones. One encouraging development has been the approval of the
proteasome inhibitor bortezomib, which functions in part by inducing accumulation of p53 and
p21, as well as other downstream p53 targets. In addition, the nongenotoxic activation of
apoptosis through exploitation of a functional p53 pathway and the use of HDM-2 inhibitors
has been shown to be an effective apoptosis-inducing strategy for solid tumor malignancies
(13), as well as hematologic malignancies such as multiple myeloma (36). Thus, our goal was
to evaluate the potential activity of such inhibitors as therapeutics in models of lymphoma.
In this work we have examined the effects of a novel inhibitor of the HDM-2/p53 interaction,
MI-63, and compared its efficacy to another agent in this class, nutlin, in a panel of NHL cell
lines, normal CD19+ B-cells, and an MCL patient sample. MCL lines with wtp53 were sensitive
to the effects of MI-63, as were patient-derived lymphoma cells, while normal PBMCs were
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much more resistant, supporting the possibility of an acceptable therapeutic index. wtp53 MCL
cell lines treated with HDM-2 inhibitors activated a p53-mediated gene expression program,
became arrested at G1/S, and were induced to undergo programmed cell death.
The HDM-2 inhibitor nutlin was originally shown to induce effects consistent with p53
accumulation, but without any effects on p53 phosphorylation (13). Our data demonstrate,
however, that both nutlin and MI-63 induce p53 phosphorylation in the MCL models used in
our study. These findings are consistent with those of Secchiero and colleagues, who reported
p53 phosphorylation at Ser-15 in B-cell chronic lymphocytic leukemia samples after exposure
to nutlin (37). Similarly, weak p53 phosphorylation was seen recently in Hodgkin Reed-
Sternberg cells (27). Since previous work with nutlins in epithelial cancer cell lines showed
no p53 phosphorylation (38), one interpretation is that these effects are specific to lymphoid
cells. However, very recent publications have demonstrated the presence of p53
phosphorylation in mouse embryonic fibroblasts at Ser-18 (39), the human homologue of
phospho-Ser-15-p53, and in primary kidney cells (40) after treatment with nutlin. Thus, it
seems likely that this may prove to be not just a cell-type, but even a cell-line-dependent effect.
Phosphorylation of p53 at serine-15 and -37 is typically the result of both genotoxic and non-
genotoxic insults. Genotoxic stresses include topoisomerase II inhibitors, nitric oxide,
hydrogen peroxide, ultraviolet light, and ionizing radiation (29), while non-genotoxic insults
include severe hypoxia and replicative senescence (29). In the comet assay, we did not observe
clear comet tails that would indicate DNA damage, and only a small amount of damage was
seen with MI-63 in the context of AP lesions. Moreover, this only induced H2AX in a small
percentage of cells, suggesting that the phosphorylation changes were largely due to
nongenotoxic mechanisms. One possibility is that the increase in phospho-Ser-15-p53 and
phospho-Ser-37-p53 levels may be due to an increase in total p53, which is then phosphorylated
to the same extent as in inhibitor-naïve cells, but more readily detected due to a greater
abundance. Indeed, densitometric scanning of immunoblots was supportive of this hypothesis
(data not shown). However, the increase in phospho-Ser-392-p53 is important since this
increases p53 tetramerization, and its ability to bind its consensus DNA sequence (41), thereby
promoting its ability to induce transactivation (42). Further studies will be needed to determine
the extent to which these phosphorylation status alterations reflect true changes in p53 function,
and whether these contribute to the apoptotic process.
HDM-2 inhibition in MCL was more effective in suppressing proliferation in JVM-2,
Granta-519, and REC-1 cells, which have wtp53, compared with Jeko-1, which has mutp53.
As expected, mutp53 Karpas-422 diffuse large cell lymphoma cells were among the most
resistant to MI-63, and this supports the role of wtp53 as the mechanism responsible for MI-63
in this cell type. A surprising finding was that MI-63 was quite potent against the mutp53 WSU-
NHL Waldenström’s cell line, and also active, albeit with an intermediate IC50, against
mutp53 CCRFCEM acute lymphoblastic leukemia cells. On the mechanistic side, this suggests
that such inhibitors are disrupting HDM-2-mediated pathways that are independent of p53.
This idea is supported by our data with pifithrin-α , which was unable to give a complete rescue
from nutlin or MI-63 in wtp53 cells. Differential effects of nutlin have been reported in cell
lines with mutant and wild-type p53 in respect to the modulation of E2F1 when nutlin was
combined with CISP (15). Our results in mutp53 cells did not require another drug, however,
and we did not observe a decrease in E2F1 in mutp53 cells (data not shown), as we did for the
wtp53 cells. We did observe an increase in p21 activation by RT-PCR in WSU-NHL cells,
which did not result in p21 protein expression, but could indicate that p73 may be acting in
these cells to induce cell death. In this regard, nutlin has previously been shown to disrupt
HDM-2/p73 interactions in wtp53, mutp53, and p53-null cells (43). However, recent studies
suggest that nutlin can have pleiotropic effects, including on pathways such as angiogenesis
(17), androgen signaling (16), and nuclear factor-κB (18). Thus, a number of candidate
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pathways will need to be studied to determine those that most contribute to the activity of these
agents in mutp53 NHL models. Also of note, MI-63 and nutlin do differ in their structures, and
while both bind residues Phe-19, Trp-23, and Leu-26 of the p53/HDM-2 interacting domain,
MI-63 also captures a fourth residue, Leu-22, which may play an important role in the
interaction between HDM-2 and p53 (24,44,45). This may allow MI-63 to serve as a more
potent inhibitor of the p53/HDM2 interaction as compared to nutlin, and may also allow it to
extend effects to mutp53 cells. We are in the process of generating cell lines resistant to MI-63,
which should aid in identifying at least some of these pathways, and may also guide the
development of future combination regimens based on these drugs.
From a clinical perspective, the validation of a new target as being of potential interest for
lymphoma therapy is encouraging, and the current findings support studies of HDM-2
inhibitors in patients with relapsed and/or refractory NHL. Combination chemotherapy is
typically a far more effective treatment modality than single agents, however, and we indeed
found that combining MI-63 with rapamycin or bortezomib displayed increased synergy
compared to conventional chemotherapeutics. Pretreatment with MI-63 was antagonistic to
chemotherapy, which is consistent with other published works demonstrating that pre-
treatment of wtp53 tumors actually protected the cells from chemotherapy-mediated toxicity.
However, similar pretreatment in mutp53 cell lines induced greater levels of apoptosis (46).
Interestingly, other work has demonstrated that nutlin is protective for kidney cells receiving
CISP therapy, and this protection appears independent of the HDM-2, HDM-4, or p53 status
of the cells (40). The potential clinical effectiveness of MI-63 is also bolstered by a recent study
of the in vivo form of this drug, MI-219, which was shown to be active in murine xenograft
models with an excellent side effect profile (25). Moreover, MI-219 plasma levels of greater
than 13μM were achieved following a single oral dose of 50mg/kg in mice (25), which are
above those which were needed in our MCL and NHL models. Taken together, these findings
support the translation of HDM-2 inhibitors such as MI-63 into the clinic both as single agents,
and in combination with other chemotherapeutics using a rational sequence of administration
that may be influenced by p53 status, for the treatment of lymphoid malignancies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. MI-63 inhibits the proliferation of non-Hodgkin lymphoma cell lines
(A) Cells were seeded in 96-well plates for viability analysis using the WST-1 reagent, and
treated with the indicated doses of MI-63 for 72 hours. WST-1 results are expressed as the
percentage cell viability in relation to the vehicle-treated sample for each cell line, which was
arbitrarily set at 100%. Experiments were performed in triplicate, and mean values with the
standard error of the mean (SEM) are shown. (B) For immunoblot analysis, cells were seeded
in 6-well plates and treated with the indicated concentrations of MI-63, vehicle, or 0.5μM
doxorubicin for 24 hours. Extracts were then probed for their content of p53, HDM-2, PARP,
and β-Actin as a loading control. A representative Western blot is shown of the triplicate
experiments performed. PARP cleavage is seen at higher concentrations of MI-63 than the
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IC50 identified in panel A because the former assays were performed for 72-hours, while the
latter were for only 24-hours, thereby requiring greater drug concentrations to induce the same
effect. (C) Granta-519 cells were treated with 10μM of the p53 inhibitor pifithrin-α alone, or
in combination with either 5μM MI-63, nutlin, or 10μM MCT as a positive control for 24 hours.
Cell viability was determined using a WST-1 viability assay. All experiments shown were
performed in triplicate and mean values are shown along with the SEM.
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Figure 2. Molecular effects of MI-63 on non-Hodgkin lymphoma cell lines
NHL cell lines were treated with DMSO, 5μM MI-63, or 0.5μM DOX as a positive control for
24 hours. (A) RT-PCR was performed to detect PUMA and p21 mRNA levels, as well as
β2M as a control. Transcripts were visualized by native gel electrophoresis. Lanes marked +RT
received 1μl of cDNA stock while those labeled 1:10 received 1μl of a 1:10 dilution of +RT.
(B) Cell extracts were probed for their content of p21 using a quantitative ELISA and compared
with a standard curve. The levels of p21 are expressed in pg/mL with the mean ± SEM from
triplicate experiments. Please note the different scale for JVM-2 cells, which had especially
high p21 levels compared with the other cell lines evaluated. (C) Cell cycle analysis was
performed of JVM-2, and REC-1, using flow cytometry. Representative profiles of one of the
triplicate experiments are shown.
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Figure 3. Caspase induction in MCL lines in response to MI-63
(A) MCL cells were treated with DMSO, 5μM MI-63, or 0.5μM DOX for 24 hours. Cellular
lysates (50μg/reaction) were then incubated with 40μM fluorogenic substrates specific for
caspases-3, 8, and 9. The results are expressed as a fold-caspase activity induction relative to
the DMSO control. (B) JVM-2 cells were treated as described above, and lysates prepared at
the indicated time points were probed for their caspase-3 activity. (C) JVM-2 cells were treated
with MI-63 for the indicated times and then evaluated by Western blotting for their content of
p53, E2F1, or β-Actin as a control.
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Figure 4. HDM-2 inhibitors induce phosphorylation of p53 and DNA damage
(A) MCL cell lines were treated with DMSO, 5μM MI-63, 5μM nutlin, or 0.5μM doxorubicin
for 24 hours, and cellular lysates were probed for their content of p53, as well as several
phosphorylated forms of this tumor suppressor, or β-Actin as a control. (B) DNA damage was
measured in JVM-2 cells after a 24-hour treatment period with 5μM MI-63, 5μM nutlin, or
0.5μM DOX using the Comet assay, of which two independent panels are shown per drug
treatment. (C) JVM-2 cells were treated with DMSO, 5μM MI-63, 5μM nutlin or 5μM cisplatin
for 24 hours, and cells were stained for cleaved caspase 3, and phospho-H2AX in combination
with either p53-phospho-Ser15 or total p53. Dual color flow cytometry was performed, and
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the percentage cells for each quadrant are shown. All experiments shown in this figure were
performed in triplicate, and results from a representative experiment are shown.
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Figure 5. MI-63 synergizes with bortezomib and rapamycin
The IC50′s of cisplatin, doxorubicin, rapamycin, and bortezomib were determined in NHL cell
lines, and then matched at a 1:1 ratio with the IC50 of MI-63. Cells were treated for 3 days,
viability was determined by the WST-1 assay, and results are expressed as the percentage
viability in relation to the DMSO control. A viability assay of JVM-2 cells treated with MI-63
alone, or in combination with cisplatin, doxorubicin, rapamycin, or bortezomib is shown.
Similar studies were performed with Granta-519, REC-1, WSU-NHL, and CCRF-CEM cells,
and used to determine the respective combination indices.
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Figure 6. Activity of MI-63 in MCL patient samples
Normal peripheral blood mononuclear cells (PBMC) and peripheral blood from an MCL
patient (MCL-1) with blastic phase disease were CD19 column purified to enrich for CD19+
B cells, and then treated with MI-63 or nutlin for 72 hours at the indicated doses. Cell viability
was determined using the WST-1 assay. (A) The viability of normal CD19+ B cells from 3
independent patients treated with HDM-2 inhibitors is shown in the left panel. Experiments
were performed in triplicate and show SEM. Proliferation of an MCL patient sample is shown
on the right. (B) CD19+ B cells from the MCL-1 patient sample were treated with DMSO,
5μM MI-63, or 0.5μM DOX for 24 hours, at which point protein lysates and RNA were
collected. Immunoblotting was performed on extracts, which were then probed for their content
of p53, HDM-2, and β-Actin. RT-PCR was performed to detect p21 mRNA levels, and β2M
was used as a control. Transcripts were visualized by native gel electrophoresis. Lanes marked
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+RT received 1μl of cDNA stock while those labeled 1:10 received 1μl of a 1:10 dilution of
+RT.
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Table 1
Combination indices (CI) of NHL cell lines treated with MI-63 and commonly used chemotherapeutic agents
The CI values were calculated after treatments described in Figure 5, and values shown are the mean of triplicate
experiments.
Drug (1× IC50) DOX CISP BZB RAP
Cell Line CI Values
JVM-2 1.0 1.3 0.5 0.4
Granta-519 0.7 0.7 2.1 0.7
REC-1 1.0 0.6 0.6 0.5
WSU-NHL 1.7 0.9 0.3 0.8
CCRF-CEM 0.9 1.0 0.9 0.6
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